Get the Stockscreener App
0.361
19.06%
-0.085
After Hours:
.34
-0.021
-5.82%
Gri Bio Inc stock is traded at $0.361, with a volume of 1.86M.
It is down -19.06% in the last 24 hours and down -28.88% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$0.446
Open:
$0.435
24h Volume:
1.86M
Relative Volume:
2.56
Market Cap:
$1.07M
Revenue:
-
Net Income/Loss:
$-13.28M
P/E Ratio:
-0.0786
EPS:
-4.5911
Net Cash Flow:
$-8.99M
1W Performance:
-14.13%
1M Performance:
-28.88%
6M Performance:
-96.35%
1Y Performance:
-99.74%
1-Day Range:
$0.3405
$0.4498
1-Week Range:
$0.3405
$0.59
52-Week Range:
$0.3405
$161.98
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Gri Bio Inc Stock (GRI) Latest News
GRI Bio secures patent in Japan for NKT cell modulators - Investing.com India
GRIGRI Bio, Inc. Latest Stock News & Market Updates - StockTitan
GRI Bio Granted Japan Patent for Proprietary Natural Killer - GlobeNewswire
GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions - StockTitan
Investor’s Delight: GRI Bio Inc (GRI) Closes Weak at 0.45, Down -10.21 - The Dwinnex
GRI’s Stock Tango: The Dance of Gains and Losses in 2023 - The InvestChronicle
Alcoholic Hepatiti Drug Industry: Insights from Latest Research Report on Business Opportunities by (2024-2034) - Talented India
Armistice Capital LLC Invests $96,000 in GRI Bio, Inc. (NASDAQ:GRI) - Defense World
Alcoholic Hepatiti Drug Industry: Insights from Latest Research Report on Business Opportunities by (2024-2034) - La Funcion mx
GRI Bio secures Australian nod for IPF treatment study - Investing.com
Brenmiller Energy Ltd (BNRG) Is A Good Stock To Invest In - Stocks Register
There is no way GRI Bio Inc (GRI) can keep these numbers up - SETE News
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia - GlobeNewswire
GRI Bio Receives Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in Australia - StockTitan
Alcoholic Hepatiti Drug Industry: Insights from Latest Research Report on Business Opportunities by (2024-2034) - Apiculture Market: Report ...
Short Interest in Galecto, Inc. (NASDAQ:GLTO) Drops By 62.1% - Defense World
Troluce Capital Advisors LLC Takes $10.98 Million Position in Summit Materials, Inc. (NYSE:SUM) - Defense World
Stock Surge: GRI Bio Inc (GRI) Closes at 0.46, Marking a 9.42 Increase/Decrease - The Dwinnex
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment - StockTitan
GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment - GlobeNewswire
Top investors say GoodRx Holdings Inc (GDRX) ticks everything they need - SETE News
Financial Health Report: Grifols SA ADR (GRFS)’s Ratios Tell a Tale - The Dwinnex
It is Poised to be a Bull Market for Grifols SA ADR (GRFS) - SETE News
Macrogenics Inc (MGNX) may enjoy gains as insiders got busy in the recent days - Knox Daily
The Potential Rise in the Price of Regenxbio Inc (RGNX) following insiders activity - Knox Daily
GRI’s price-to-free cash flow ratio: How it affects investment decisions - US Post News
The Future of Gorilla Technology Group Inc: Analyzing GRRR - The InvestChronicle
Grindr Inc [GRND] Insider Selling: Time to sell? - Knox Daily
Closing Strong: GRAIL Inc. (GRAL) Ends at 13.04, Down -6.52 from Last Close - The Dwinnex
Masterton Capital Management LP Grows Holdings in Regency Centers Co. (NASDAQ:REG) - Defense World
Leerink Partners initates Geron Corp. (GERN) rating to an Outperform - Knox Daily
Hancock Whitney Corp Sells 964 Shares of Gibraltar Industries, Inc. (NASDAQ:ROCK) - Defense World
Resources Connection, Inc. (NASDAQ:RGP) Shares Sold by Hancock Whitney Corp - Defense World
Amalgamated Bank Has $3.36 Million Holdings in Repligen Co. (NASDAQ:RGEN) - Defense World
Garmin Ltd. (NYSE:GRMN) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
American Century Companies Inc. Increases Position in Granite Ridge Resources, Inc. (NYSE:GRNT) - MarketBeat
Analyzing Grindr (NYSE:GRND) & Blue Sphere (OTCMKTS:BLSP) - Defense World
Gritstone bio (NASDAQ:GRTS) Trading Down 7.4% - Defense World
India's G R Infraprojects rises on project bid - XM
Keeping an Eye on Green Brick Partners Inc (GRBK) After Insider Trading Activity - Knox Daily
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference - Longview News-Journal
Vallon Pharmaceuticals stock plunges to 52-week low of $0.4 - Investing.com
Vallon Pharmaceuticals stock plunges to 52-week low of $0.4 - Investing.com India
Geron (NASDAQ:GERN) Stock Price Down 4.5% - MarketBeat
MGNX Deadline in 1 Day: Kessler Topaz Meltzer & Check, LLP Reminds MacroGenics, Inc. (MGNX) Investors of Filing Deadline in Class Action Lawsuit - Markets Insider
GoodRx Holdings Inc (GDRX)’s Market Momentum: Closing Strong at 6.91, Down -2.40 - The Dwinnex
Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $55.80 - MarketBeat
Financial Metrics Check: Macrogenics Inc (MGNX)’s Ratios for Trailing Twelve Months - The Dwinnex
The Gorman-Rupp Company (NYSE:GRC) Shares Sold by Gabelli Funds LLC - Defense World
Examining Gorilla Technology Group Inc (GRRR) more closely is necessary - US Post News
Gritstone Bio Inc (GRTS) stock: A year of ups and downs - US Post News
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):